Introduction
Neurodegenerative diseases constitute a broad group of disorders including Alzheimer's, Parkinson's and Huntington's disease, which all share the feature of progressive loss of neurons in the central nervous system (CNS). Some of these diseases show hotspots of degeneration, such as the substantia nigra in Parkinson's disease (PD), and are therefore well suited for gene therapy using focal injections of vectors delivering therapeutic genes. There are two prerequisites for the successful and safe use of such vectors: targeted and efficient delivery as well as long-term expression of the therapeutic gene in specific cell populations such as postmitotic neurons, since expression in unintended cells may prove pathogenic. Lentiviral vectors are ideal candidates for such gene delivery tools, since they have been shown to transduce dividing as well as nondividing cells, resulting in stable integration and long-term expression of the transgene. [1] [2] [3] [4] The tropism of lentiviruses is determined in part by the interaction of the viral surface glycoproteins with receptor molecules expressed on the cell surface, and this can be modified by the incorporation of heterologous glycoproteins derived from other enveloped viruses. 5 This phenomenon, referred to as pseudotyping, can be used to achieve selective entry into specific target cells by taking advantage of the natural tropism of heterologous envelope proteins, and can thereby increase the efficiency and safety during in vivo transfer of various therapeutic agents.
So far, successful in vivo transduction of the brain parenchyma of rodents has been demonstrated with lentiviral vectors derived from human immunodeficiency virus 1 (HIV-1), 1, 3 simian immunodeficiency virus (SIV), 6 feline immunodeficiency virus (FIV), 7, 8 and equine infectious anemia virus (EIAV). 9 All of these vectors were able to generate infectious pseudotypes with glycoproteins derived from different viruses, that is, the vesicular stomatitis virus (VSV), Ebola virus, Marburg virus, rabies virus (RV), lymphocytic choriomeningitis virus (LCMV), Mokola virus, murine leukemia virus (MLV), influenza virus, gibbon ape leukemia virus (GALV), Ross River virus (RRV) and others as shown in in vitro infection experiments (for review see Cronin et al. 10 ). Some of these pseudotyped vectors have already been analyzed for their in vivo transduction pattern in the brain. 6, 9, [11] [12] [13] [14] [15] However, no data are available so far comparing differently pseudotyped SIV-based lentiviral vectors used to infect brain parenchyma.
The surface glycoprotein from VSV, which is commonly used for pseudotyping of lentiviral particles, has been shown to confer a preference in transduction of neuronal over glial cells after direct application into the brain, a phenomenon which remains largely unexplained, since it is known that a ubiquitously distributed phospholipid receptor is used for viral entry. 1, 3, [16] [17] [18] Nevertheless, entry of vectors coated with other heterologous envelopes such as the G-protein of rabies virus was demonstrated to be more limited to cells that express the appropriate neuronal cellular receptor. 13 Another important aspect when analyzing pseudotyped vectors is the fact that replacement of the original envelope alters not only the transducing qualities of the virus but also its physico-chemical properties such as the stability of the particle and the interaction of the envelope with the host immune system, respectively, which can have an influence on viral particle production and in vivo transduction rates. 19, 20 One of the major concerns for the use of lentiviral vectors for human gene therapy is the issue of biosafety. It is not clear yet which type of vector, derived from either primate or nonprimate lentiviruses, will have better chances to be accepted for future gene therapy approaches. 21, 22 Vectors derived from SIV [23] [24] [25] [26] [27] are potentially good candidates, but until now only limited studies have been carried out to evaluate their transduction efficiency and safety, particularly after administration to the brain. 6, 28 In this study, we comparatively evaluated various pseudotyped SIV-based vectors for their infectivity of neuronal and non-neuronal cells, their stability during concentration to high virus titer stocks and their in vivo transduction pattern after stereotactic injection into the mouse brain. Our data indicate that SIV vector particles can be efficiently pseudotyped with VSV-G, LCMV-G protein (LCMV-GP), RRV-G protein (RRV-GP), RV-G protein (RV-G) and the amphotropic MLV 4070A envelope protein (MLV4070Aenv), and that each pseudotype can be concentrated to generate high-titer viral stocks. Infection analyses of dissociated primary mouse brain cultures revealed transduction of both neuronal as well as glial cells. Transduction experiments performed in vivo, in contrast, showed that only VSV-G pseudotypes infect neurons and glial cells, whereas particles pseudotyped with all other heterologous envelopes transduce glial cells only. Transduction efficiencies quantified in vivo were highest for VSV-G-pseudotyped vectors, followed by RV-G, LCMV-GP, RRV-GP and MLV4070Aenv pseudotypes with more than 10-, 15-, 140-and 500-fold lower transduction rates.
Our studies also evaluated the influence of the central polypurine tract (cPPT) and the central termination sequence (CTS) in SIV vectors for brain transduction, since this sequence is described to act as a cis-active determinant of the import of the lentiviral genome into the nucleus of nondividing cells. 29, 30 VSV-G-pseudotyped SIV vectors with the cPPT/CTS led to fourfold higher transduction efficiencies as compared to vectors lacking the cPPT/CTS, and were able to infect neurons as well as glial cells, whereas those not containing the cPPT/CTS region mainly transduced only glial cells.
Evaluation of vector immunogenicity performed with the VSV-G-pseudotyped SIV vector carrying the cPPT/ CTS after stereotactical delivery into the brain indicates a humoral immune response against the VSV-G protein.
Biodistribution analyses, however, using this vector revealed no vector-specific sequences in any of the tested organs besides the brain.
Results

Cell specificity of pseudotyped SIV vectors in vitro
A selection of heterologous envelope proteins derived from amphotropic MLV, VSV, LCMV, RRV and RV were analyzed for their ability to pseudotype an SIV-derived lentiviral vector. Viral particles were produced by transient co-transfection of 293T cells with the vector plasmid pViCGDBH, the packaging plasmid pSgpD2 and the different envelope expression plasmids pCMVAXF, pHCMV-G, pHCMV-LCMV-GP, pRRVpcDNA3.1Zeo+ and pHCMV-RabiesG, coding for the MLV4070Aenv, the VSV-G, the LCMV-GP, the RRV-GP and the RV-G surface proteins, respectively ( Figure 1 ). Viral particles were harvested after 48 h and the infectious titer was determined by serial dilution of the viral supernatant and transduction of target cells. Fluorescence-activated cell sorting (FACS) analysis for eGFP fluorescence 72 h after infection revealed successful pseudotyping of SIV vectors with all envelopes analyzed since infectious titers on HeLa cells were in the range of 10 7 green fluorescing units (GFU)/ml for VSV-G pseudotypes, 10 5 GFU/ml for MLV4070Aenv, LCMV-GP and RRV-GP pseudotypes and 10 4 GFU/ml for RV-G pseudotypes ( Figure 2 ). Evaluation of the physical titer determined by reverse transcriptase (RT) activity measurements of the different pseudotyped vectors revealed differences of virion-associated RT activity in the range of only fivefold (data not shown). Thus, the lower infectious titers observed with some pseudotypes seem to result rather from a lower capacity to transduce HeLa cells than from differences in the amount of infectious viral particles.
VSV-G-pseudotyped particles, as compared to the other pseudotyped vectors, resulted, on average, in 2-to 3-log higher transduction rates in all other cell lines tested, such as the human neuroblastoma cell line SH-SY5Y, the murine neuroblastoma cell line Neuro2a and the rat neural cell line HiB5 (Figure 2a) . In detail, VSV-G-pseudotyped vector particles revealed an infectious titer of about 1 Â 10 7 GFU/ml in all cell lines tested with the exception of Neuro2a cells, in which titers were approximately 25-fold lower ( Figure 2a) . Interestingly, RV-Gpseudotyped viral vectors revealed a 71-and 15-fold higher transduction rate of SH-SY5Y and HiB5 cells than of HeLa cells, respectively, suggesting a strong preference of RV-G-pseudotyped vectors for infection of neuronal cell lines. However, Neuro2a cells, which were generally hard to infect, did not indicate any transduction preferences for RV-G-pseudotyped vector particles ( Figure 2a , Table 1) .
Primary dissociated brain cell cultures were derived from the mesencephala of fetal mice and infected with the differently pseudotyped SIV-vectors with a similar reverse transcriptase activity in the viral particles of 1.3 Â 10 13 pU/ml. Immune histochemical double labeling of the cells using antibodies against eGFP (shown in green) and cell type-specific markers (shown in red) was performed 9 days post infection. Antibodies against NeuN (neuronal nuclear antigen) and GFAP (glial fibrillary acidic protein) were used to label neurons and astroglial cells, respectively. Infection of both cell types following the application of all pseudotyped vectors could be demonstrated (Figure 2b ). Qualitative evaluation of representative cell cultures, however, suggested a slightly increased number of transduced neurons using VSV-G-pseudotyped SIV vectors as compared to vectors pseudotyped with all other glycoproteins (Figure 2b ).
Enrichment of pseudotyped SIV vector particles
In vivo transduction of neuronal tissue using lentiviral vectors requires concentration of vector particles to achieve high titer viral stocks. However, as pseudotyping alters not only the tropism of viral particles but might also change their stability, each pseudotype vector was tested for its ability to be concentrated via ultracentrifugation. High-titer virus stocks were generated by pelleting particles via ultracentrifugation at 50 000g for 120 min at 41C. Infectious titers of the viral preparations before and after concentration were determined. All vector pseudotypes were able to be efficiently concentrated, allowing recovery of, on average, more than 50% of the infectious particles after a 100-fold concentration step (Table 2 ). Thus, consistently high biological titers of about 10 6 GFU/ml for MLV4070Aenv-pseudotyped vectors, 10 7 GFU/ml for LCMV-GP, RRV-GP and RV-G-pseudotyped vectors and 10 8 GFU/ml for VSV-Gpseudotyped vectors could be obtained. This allows high-level gene transfer after intraparenchymal injection into the mouse brain where only small volumes can be applied.
Evaluation of pseudotyped SIV vector transduction efficiency and specificity in mouse brain
The transduction efficiency of the pseudotyped SIV vectors was initially analyzed by stereotactically injecting 4 ml of highly concentrated vector particles pseudotyped with VSV-G (2.4 Â 10 8 GFU/ml) into the right striatum of adult C57Bl/6 mice (n ¼ 4). Animals were killed 2 weeks after vector administration, and transduction rates were assessed by serial sectioning of the brain and eGFPspecific immunostaining of the sections. Intraparenchymal injection of the SIV vector resulted in high-level transduction of many cells not only at the site of injection in the striatum (Figure 3b , lower box) but also in the overlying corpus callosum (Figure 3b, upper box) . The calculated anterior-to-posterior extent of eGFP expression was up to 1.5 mm (Figures 3a-c) , indicating that in vivo delivery of VSV-G-pseudotyped SIV vectors led to highly efficient in vivo transduction of brain parenchyma. No or only weak gross signs of inflammation were observed in the transduced areas.
For comparison of transduction efficiency and specificity of the SIV vectors pseudotyped with LCMV-GP, RRV-GP, RV-G, MLV4070Aenv and VSV-G, again, 4 ml of concentrated vector preparations were stereotactically injected into the striatum of the right hemisphere of adult C57Bl/6 mice (n ¼ 5 per pseudotype). Beforehand, vector stocks were normalized to the amount of RT per volume of vector supernatant, which was within a range of 6 Â 10 6 to 2 Â 10 7 pg/ml. Two weeks after infection, brains were removed and immunohistochemically analyzed for eGFP expression, and the volume of eGFPpositive cells within the right striatum and corpus callosum was stereologically quantified. Transduction rates differed greatly among the various pseudotyped vectors and different phenotypes of transgene expressing cells were found (Figure 4) . Injection of VSV-G-pseudotyped SIV vectors showed the most efficient gene transfer (Figure 4a ), where 1.96% (median) of striatum and corpus callosum in the analyzed sections were found to be eGFP positive. Higher magnification of the morphology of the transduced cells revealed that 
Presence of the cPPT/CTS influences SIV vector transduction efficiency and specificity in vivo
It has previously been shown that cPPT acts as a cisactive determinant of lentiviral genome import into the nucleus of nondividing cells and that reinsertion of the cPPT/CTS sequence into HIV-1-derived vectors improves gene transduction in vivo, for example in neurons of the brain.
14, 30 We thus compared transduction efficiencies of SIV vectors with and without the cPPT/CTS region. VSV-G-pseudotyped vector particles were produced via transient transfection of 293T cells, and infectious titers were evaluated via serial transduction of HeLa cells, revealing a mean infectious titer of 3.30 (70.9) Â 10 7 GFU/ml with vector ViFCGDBH carrying the cPPT/CTS sequence and 1.43 (70.05) Â 10 7 GFU/ml with vector ViCGDBH lacking this sequence. These data indicate that the presence of the cPPT/CTS in vectors derived from SIV is able to stimulate gene transfer in vitro, revealing a 2.3-fold increased infectious titer with vector particles containing the cPPT/CTS than with particles lacking this sequence. To analyze whether the cPPT/CTS sequence has an influence on the transduction efficiency in vivo, 2 ml (1 Â 10 7 pg RT/ml) of VSV-Gpseudotyped SIV vectors with and without the cPPT/ CTS were stereotactically injected into the striatum of adult C57Bl/6 mice. To ensure injection of the same amount of viral particles, vector preparations were titrated beforehand according to their RT activity. Treated mouse brains were analyzed for eGFP expression 2 weeks later. The in vivo transduction efficiency of the SIV vector lacking the cPPT/CTS (SIV-cPPT; Figure 6Aa ) was fourfold (2.3-to 5.9-fold) (median (minimummaximum)) reduced as compared to that of the SIV vector carrying the cPPT/CTS sequence (SIV+cPPT; Figure 6Ab ).
Transduction of primary brain cell cultures with both vectors, followed by subsequent immune histological double labeling with eGFP/GFAP-specific and eGFP/ NeuN-specific antibodies, respectively, revealed that neurons as well as glial cells have been infected and express the transgene ( Figure 6B ). After stereotactic delivery of the vectors into the mouse brain, SIV-cPPTtransduced and eGFP-expressing cells in the striatum (Figure 6Ca ) as well as in the corpus callosum ( Figure  6Cd ) had glial appearance, with astroglia-as well as oligodendroglia-like morphology, whereas no eGFPexpressing cells with neuronal appearance were detectable. In vivo data obtained with vector SIV+cPPT showed that glial as well as neuronal cells have been infected (Figures 4f and k and Figures 5a-d) . These results are supported by data from immunohistochemical double labeling of cells transduced with vector SIV-cPPT, with the neuron-specific marker NeuN and the astrocytespecific marker GFAP. Subsequent laser scanning immune fluorescence microscopy of the labeled samples revealed that the vast majority of eGFP-expressing cells found in the striatum (Figure 6Cc ) and in the corpus callosum (Figure 6Cf ) also express the astrocytic marker GFAP, whereas none of the eGFP-expressing cells in either of these regions co-labeled with the neuronal marker NeuN (Figure 6Cb and Ce). Thus, in vivo, the SIV vector lacking the cPPT/CTS was able to efficiently transduce glial cells such as astrocytes, but, in contrast to HIV-1 vectors which allow transduction of neurons even when lacking the cPPT/CTS, 1, 31 it was unable to infect neurons.
Analysis of immunogenicity and biodistribution of VSV-G-pseudotyped SIV vectors
To analyze the humoral immune response to the VSV-Gpseudotyped SIV vector, 3 Â 10 6 vector particles were stereotactically injected into the striatum, and serum was collected 5 weeks later. VSV-G-specific signals were detected in western blot analyses with serum from four out of five mice tested ( Figure 7, lanes 4-8) , revealing a substantial production of VSV-G-specific antibodies. Biodistribution of vector particles was determined 2 weeks after intracranial delivery of VSV-G-pseudotyped vector particles as described above by using a highly sensitive real-time PCR approach, 32 to screen for eGFPspecific sequences in cells of brain, salivary gland, lymph nodes, esophagus, lung, heart, liver, kidney, spleen, colon, testis, bone marrow and blood. No eGFP-specific signals were obtained in any of the organs tested except in the injected brain hemisphere (data not shown).
In summary, our data indicate that lentiviral vectors based on SIV can be used for an efficient and targeted transduction of brain cells. This enables not only the application of SIV vectors as gene therapy vehicles for animal models of neurodegenerative diseases but might also prove useful in developing novel gene therapeutic strategies for humans.
Discussion
Lentiviral vectors are among the most useful tools for gene transfer to the CNS due their ability to transduce slowly or nondividing terminally differentiated cells, to stably integrate into the cellular genome and thus to mediate long-term gene expression. [1] [2] [3] [4] 33 So far, most and EIAV. 9, 13, 15, 38 In this study, we have evaluated the suitability of SIV as a vector system to target cells in the mouse brain. Pseudotyping of SIV vectors with the surface proteins of VSV, rabies virus (RV), LCMV, RRV and MLV revealed efficient transduction of neuronal cell lines in vitro, and, as reference, of HeLa cells. Only with RV-G-pseudotyped particles were higher transduction rates obtained in most of the neuronal cell lines than in HeLa cells (Figure 2a) . The murine neuronal Neuro2A cell line was most poorly SIV vector pseudotyping B Liehl et al transduced by almost all pseudotyped SIV vectors, as compared to neuronal cell lines of rat and human origin (Figure 2a) , probably due to the presence of an SIVspecific restriction factor in mouse cells. 39 Transduction efficiency in vivo was evaluated after injection of highly concentrated pseudotyped SIV vector stocks into the striatum of adult mouse brains and revealed clear differences among the pseudotyped SIV vectors. With VSV-G-pseudotyped viral particles, which demonstrated the highest in vivo transduction efficiencies, about 2% of the striatum and corpus callosum within the analyzed brain region were positive for eGFP expression. LCMV-GP-and RV-G-pseudotyped vectors demonstrated only moderate in vivo transduction efficiencies, more than 10-fold lower than VSV-Gpseudotyped vectors, and MLV4070Aenv and RRV-GPpseudotyped vectors exhibited only poor transduction potential, despite the fact that, as determined by reverse transcriptase activity, similar viral titers were applied. This is in contrast to data obtained using pseudotyped HIV vectors injected into mouse striatum.
14 There, evaluation of the transduction efficiency, abeit of a qualitative nature, revealed that MLV4070Aenv-pseudotyped particles were at least as effective as VSV-G-pseudotyped vectors, leading to efficient striatal transduction, but that injection of LCMV-GP-pseudotyped HIV particles resulted in only marginal transduction. 14 Wong et al. 15 reported minimal transduction using LCMV-GP-pseudotyped EIAV virus vectors, but similarly, high numbers of infected cells following stereotactic injection of RV-G-and VSV-G-pseudotyped vector particles into the striatum of rats. One reason for the observed differences between these and our studies might be that we quantified and normalized the amount of injected viral particles via their RT activity, whereas in all other studies this was achieved via the infectious titers on cultured cells derived from different species and tissues, which are not necessarily indicative of their in vivo transduction capacity in brain tissue.
In this study, the evaluation of the cellular tropism of pseudotyped lentiviral SIV vectors in mouse brain revealed that VSV-G-pseudotyped vector particles transduced glial as well as neuronal cells, albeit to a lesser extent, whereas all other envelopes tested mediated preferential transduction of neuroglial cells (Figures 4  and 5) . VSV-G mediates viral entry through interaction with a phospholipid component of the cell membrane, rather than through interaction with a specific receptor protein, thus conferring an extremely broad host cell range on VSV-G-pseudotyped vectors. The VSV-G protein has been shown to direct widespread transduction of brain cells using other lentiviral vectors based on HIV, EIAV and FIV, allowing entry into both glial and neuronal cells. 12, 13, 18, 35, 40, 41 However, several studies have reported a predominant transduction of neurons in the striatum of the rodent brain using such VSV-G-pseudotyped vectors. 1, 3, 4, 12, 13, 17, 18, 41 Very recently, Kitagawa et al. 28 directly compared VSV-G-pseudotyped HIV-1 and SIVmac-based lentiviral vectors after stereotactic delivery to the brain of rats and monkeys and observed a clear preference of the HIV-1 vector for the transduction of neurons as compared to glial cells, whereas the SIV vector preferentially infected glial cells. In rats, the ratio of infected neuronal to infected glial cells was more than 15-times higher in HIV-1-than in SIV-transduced brains, clearly indicating the influence of a lentivirus-specific component in the infection of different cell types in the brain. 28 Most of the other heterologous envelopes used for pseudotyping are described to interact with specific receptors. The amphotropic MLV4070A envelope and the LCMV-GP, for example, recognize a sodium-dependent phosphate transporter (Ram-1/Pit-2) 42 and a-dystroglycan, 43 respectively, both of which are widely expressed in cells of the CNS. 42, 44 Nevertheless, in accordance to our data obtained in mice, Miletic et al. 45 have shown an almost exclusive transduction of astrocytes in the rat striatum using LCMV-GP-pseudotyped HIV vectors. The cellular receptors responsible for the binding of the RRV-GP are currently unknown, but it is likely that this envelope protein either utilizes multiple receptors to gain access to cells and/or uses ubiquitous proteins as cellular receptors, since RRV has a broad host range. However, this study as well as data obtained by Kang et al. 12 revealed RRV-pseudotyped lentiviral vectors to transduce predominantly neuroglial cells. The rabies virus G-protein has been shown to interact with many neuronal receptors such as the p75 low-affinity neurotrophin receptor, the neural cell-adhesion molecule and the nicotinic acetylcholine receptor. Hence, RV-Gpseudotyped EIAV vectors injected into the rat striatum resulted in transduction of mainly neuronal cells. 13, 15 Interestingly, although we obtained pronounced transduction of glial cells after injection of SIV vector particles pseudotyped with the RV-G protein, no transduced and eGFP-expressing neuronal cells could be detected. This is in accordance with preliminary data from Watson and colleagues, 14 where injection of an RV-G-pseudotyped HIV vector into the mouse striatum also did not result in transduction of neuronal striatal cells. They speculate that receptor differences between rat and mouse brain cells in the striatum may explain the observed SIV vector pseudotyping B Liehl et al differences in transduction specificity obtained with vectors pseudotyped with the same strain of RV-G. 14 In our experiments, we have used the G-protein of a different rabies virus strain, which might also account for differences in the transduction pattern, as the binding affinity of RV-G to neural cell receptors might well depend on the RV strain.
The cPPT is normally found in the pol region of the lentiviral genome and, together with the central termination sequence (CTS), directs the formation of the DNA flap during reverse transcription. 46 It has been suggested that the DNA flap interacts with host factors to favor translocation of the vector preintegration complex across the nuclear membrane 29 and optimal infectivity of nondividing cells appears to require this cis-acting element. Efficient transduction of neurons in the brain using HIV-1-derived cPPT/CTS-defective vectors has been reported, 1, 31 but others have shown that they perform less efficiently. 30 Here, we analyzed the influence of cPPT/CTS sequence on the transduction level and specificity of SIV by initially comparing the infectious viral titers of VSV-G-pseudotyped particles with and without cPPT/CTS, respectively, in vitro. The presence of the cPPT/CTS led to a reproducible increase in vector titer of about 2.3-fold, in accordance to published data, where the insertion of the cPPT/CTS in SIV-and HIV-1-derived vectors also caused a two-to threefold increase in infectious vector titer. 23, 46 Furthermore, after in vivo application, SIV vectors carrying the cPPT/CTS resulted in fourfold higher infection efficiencies compared to vectors without the cPPT/CTS, rendering its presence beneficial for improvement of transduction levels in the mouse brain ( Figure 6A) .
With respect to the cell type specificity of these vectors, infection of primary dissociated brain cultures with both vector types SIV+cPPT and SIVÀcPPT, respectively, was shown to result in transduction of neuronal as well as glial cells, whereas following intrastriatal injection only cPPT/CTS harboring vectors were able to transduce neuronal as well as glial cells. Deletion of the cPPT/CTS led to a loss of neuronal cell transduction in vivo, resulting in infection of glial cells such as oligodendrocytes and astrocytes only (Figure 6c ). These different findings could be due to the better accessibility of neurons in cell culture or to the different extracellular environment found in cell culture and in the living animal, respectively. In rats, however, Stitz et al. 6 have described the in vivo transduction of neuronal cells using a VSV-G-pseudotyped SIVagm-based vector lacking the cPPT/CTS sequence, and, in addition, HIV-1-based vectors lacking the cPPT/CTS were also shown to be able to transduce neurons in rat brain. 1, 31 However, a weak tropism of SIV for neurons, as shown by Kitagawa et al. 28 in combination with the poor infectability of murine neuronal cells, as suggested from our in vitro data (Figure 2a) , might render the presence of the cPPT/ CTS sequence essential for SIV vector-mediated in vivo transduction of terminally differentiated murine neuronal cells.
We also carried out initial studies on the biosafety profile of SIV-based lentiviral vectors following intracranial administration, by examining the potential for escape of the vector from the brain and a systemic immune response. A quantitative real-time PCR assay used to evaluate biodistribution showed that vector integration events were limited to the injected sites since we were unable to detect any transgene-specific sequences in a wide spectrum of body tissues. Interestingly, an antibody-mediated immune response against the VSV-G protein was observed in the sera of four out of five vector injected mice (Figure 7) . The underlying mechanisms for the production of humoral antibodies in these mice is not known, but has also been observed following intracranial injection of HIV-1-based vectors. 34, 47 There, the authors speculated, that transient disruption of the blood-brain barrier during stereotactic operation may be sufficient to elicit an immune response to vector proteins. Abordo-Adesida et al., 48 in contrast, observed no humoral immune response to viral proteins following intracranial injection of an eGFP gene carrying HIV vector. Only after subsequent subcutaneous immunization again using this vector or a vector expressing a different transgene, could antibodies against viral proteins, including VSV-G, be elicited. 48 Although vector systems, mainly based on HIV, EIAV and FIV, have been successfully utilized for gene transfer to the brain, it is not clear at present which type of lentiviral vector, derived from either primate or nonprimate lentiviruses, has the best chance to be accepted for future gene therapy approaches. In this study, we have thus analyzed the transduction efficiencies and patterns of various pseudotyped SIV-derived lentiviral vectors in mouse brain, and were able to show high-level transduction of brain parenchyma targeted predominantly to glial cells. This might prove advantageous for the application of SIV vectors as gene-delivery vehicles for the treatment of CNS disorders such as leukodystrophies, lysosomal storage or demyeliating diseases, in which mainly glial cells are affected.
Materials and methods
Plasmids
To construct plasmid pViFCGDBH, a 155 bp fragment of the cPPT/CTS region was amplified by PCR using primers cPPTfor (5 0 -CGCCCGGGTTTAAAAGAAGGGGAGGAA-3 0 ) and cPPTrev (5 0 -CACCCGGGTGCCTTCTCTGTAATA GAC-3 0 ) and inserted into plasmid pViCGDBH. 26 The integrity of the cPPT/CTS was determined by sequencing. Construction of plasmid pCMVAXF encoding the MLV4070A envelope gene under control of the human cytomegalovirus (CMV) promoter was carried out by inserting the NruI/EcoRV fragment of plasmid pcDNA3 (Invitrogen, Lofer, Austria) into the large blunt-ended NdeI/AccI fragment of pAXF. 49 Plasmid pHCMVRabiesG encoding the G-protein of rabies virus under control of the human CMV promoter was derived from pHCMV-LCMV-GP, 50 by replacing the LCMV-GP open reading frame (ORF) with the G-protein of rabies virus strain SAD B19. 51 To this end, the EcoRV/SmaI fragment of plasmid pT7T-G containing the rabies virus G-protein cDNA was inserted into the large blunt-ended BamHI fragment of plasmid pHCMV-LCMV-GP.
Cell culture, vector production and concentration
The human embryonic kidney cell line 293T (ATCC CRL-11268), the human cervical adenocarcinoma cell line HeLa (ATCC CCL-2), the murine neuroblastoma cell line Neuro2a (ATCC CRL-131) and the rat neural cell line SIV vector pseudotyping B Liehl et al HiB5 52 were maintained in Dulbecco's modified Eagle's medium (DMEM, Invitrogen) supplemented with 10% heat-inactivated fetal calf serum (FCS, Invitrogen). The human neuroblastoma cell line SH-SY5Y (ATCC CRL-2266) was maintained in a 1:1 mixture of Ham's F-12 medium (Invitrogen) and minimum essential medium (MEM, Invitrogen) supplemented with 1% nonessential amino acids (Invitrogen), 2 mM L-glutamine (Invitrogen) and 10% heat-inactivated FCS.
Pseudotyped lentiviral vector particles were generated from 293T cells co-transfected with packaging and vector constructs using the standard calcium phosphate co-precipitation method. 53 Either 5 Â 10 5 293T cells were seeded in six-well plates or, for larger scale studies, 4 Â 10 6 cells were seeded in 10 cm dishes and transiently co-transfected after 24 h with 2 and 12 mg of the lentiviral vector plasmids pViCGDBH or pViFCGDBH, 1.5 and 9 mg of the packaging plasmid pSgpD2 26 and 0.5 and 3 mg of one of the following env-expression plasmids, respectively: pHCMV-G 54 encoding the VSV-G protein, pCMVAXF encoding MLV4070Aenv, pHCMV-LCMV-GP 50 encoding the LCMV-GP, pRRVpcDNA3.1Zeo+ 12 encoding the RRV-GP and pHCMV-RabiesG encoding the surface glycoprotein of rabies virus. Sixteen hours after transfection, medium was removed and the cells were supplemented with 2 and 12 ml DMEM containing 10% FCS respectively. Vector supernatants were harvested 48 h later, filtered through a 0.45 mm pore size filter and used for infection. For the generation of high-titer vector stocks via ultracentrifugation, pseudotyped viral vectors were pelleted at 50 000 g for 1.5 h at 4 1C using an SW40 Ti swinging bucket rotor (Beckman, Krefeld, Germany) according to the method described by Naldini et al.,
1 then resuspended in serum-free DMEM in 1/100 of the initial volume, aliquoted and stored at À80 1C.
Titer estimation of pseudotyped vector particles
Infectious titers of vector supernatants were determined on various target cells. HeLa, Neuro2a and HiB5 cells were seeded in six-well plates at a density of 2.5 Â 10 5 cells per well and SH-SY5Y cells at a density of 5 Â 10 5 cells per well. Twenty-four hours later, the cell culture medium was replaced by 10-fold serial dilutions of viral supernatant in a total volume of 1 ml DMEM/10% FCS, and 8 mg/ml polybrene (Sigma, Vienna, Austria) was added. Six hours after inoculation, 1 ml of fresh medium was added. Seventy-two hours post infection cells were trypsinised, washed twice with phosphate-buffered saline (PBS) and subjected to FACS analysis to determine transduction efficiencies by counting the number of eGFP expressing cells. Virus titer was calculated according to the formula: GFU/ml ¼ (%eGFP-positive/100) Â dilution factor Â cell number. To ensure maximum accuracy, we calculated the titer only from transductions with dilution factors that resulted in more than 1% and less than 30% of eGFP-expressing cells.
Physical titers reflecting viral particles in the supernatant, which reveal RT activity, were determined using a colorimetric RT immunoassay (RetroSys, Innovagen AB, and 1/53405.75, respectively. The RT concentration of the samples was determined from a regression line calculated from the HIV-1 rRT standard curve. Only samples with RT activities within the linear measuring range of the plate reader and with absorbance signals greater than two times the mean of the background controls were used for further calculations. The mean RT activity present in each sample dilution was expressed as the corresponding amount of reference RT having equal activity, since the reference RT was not derived from the same virus type, and thereby may exert a different enzymatic activity.
Preparation and infection of primary dissociated brain cell cultures
Pregnant mice (OF1/SPF, Biomodels Austria, Vienna, Austria) at gestation day 14 were killed, and the embryos were carefully removed and transferred to a petri dish containing PBS. Brains of the embryos were excised and primary cell cultures were prepared according to Radad et al. 55 Briefly, after excision of the ventral mesencephala, the meninges were carefully removed and tissues were mechanically cut into small pieces in PBS and subsequently triturated with a fire-polished Pasteur pipette in DMEM. Dissociated cells were resuspended in DMEM containing 10% FCS, 25 mM Hepes, 2 mM glutamine and 30 mM glucose. The cell suspension was pipetted into four-well chamber slides pre-coated with 50 mg/ml poly-D-lysine (Nunc, Wiesbaden, Germany). The culture medium was changed after 24 and 72 h. On day 5 of in vitro cultivation, serum was reduced to 5% and 1% B27 supplement (Gibco, Lofer, Austria) was added to the medium and on day 6, culture medium was changed to serum-free DMEM containing 2% B27 supplement. One day later, dissociated brain cultures were infected with lentiviral vectors either adjusted to the same RT activity (1.3 Â 10 13 pU/well), to compare the differently enveloped vectors, or adjusted to 1 Â 10 7 infectious virus particles as determined on HeLa cells, to analyze the effect of the cPPT/CTS. Nine days post infection, cells were fixed using accustain solution (Sigma) and histologically analyzed as described below.
Delivery of vector particles into the striatum
For comparison of the in vivo transduction capacity of various pseudotyped vectors, adult C57Bl/6 mice of both sexes were used. The mice were maintained with food and water available ad libitum, and all surgical procedures were conducted according to the Austrian Animal Experimentation Laws. For stereotactic surgery, animals were anesthetized by intraperitoneal injection of 10 mg ketamin/0.4 mg xylazine per 100 g body weight and placed in a small-animal stereotactic apparatus with the skull horizontal between lambda and bregma. After midline incision of the skin, a hole was drilled in the skull and up to 4 ml highly concentrated vector particles were injected into the right striatum at a rate of 0.5 ml/ min with a 26-gauge needle on a 5-ml Hamilton syringe. Coordinates to target the striatum were 5 mm anterior, 2 mm lateral and 3.5 mm ventral to lambda, as measured from the skull surface according to Paxinos and Franklin. 56 During the injection process, the needle was raised slowly in the dorsal direction over a distance of 1 mm. After injection, the needle was left in place for SIV vector pseudotyping B Liehl et al additional 5 min before being slowly removed. Following injection, the incisions were sutured and animals were kept under observation until recovery.
Histological analysis
Mice were euthanised under anesthesia 2 weeks post injection of the vector by transcardial perfusion with 10 ml cold PBS and 10 ml accustain solution (Sigma). The brains were removed immediately from the skull and postfixed by immersion in the same fixative for another 4 h at 41C. After paraffin embedding, tissues were sectioned coronally (3 mm thick) and mounted onto poly-L-lysine coated slides. For immunohistochemical detection of eGFP expression, sections were deparaffinized, rehydrated and immersed in 3% hydrogen peroxide in methanol for 15 min to inactive endogenous peroxidase. The slides were then incubated overnight with a rabbit anti-eGFP antibody (Molecular Probes, Lofer, Austria, 1:4000) and a horseradish peroxidase (HRP)-conjugated goat antirabbit antibody (Dako, Vienna, Austria). Immune-reactivity was visualized using diaminobenzidine tetrahydrochloride (DAB) as chromogen.
Tissue sections were counterstained with hematoxyline, a coverslip placed over the section and analyzed with a Zeiss light microscope, and images were captured (Axiovision Systems, Zeiss, Jena, Germany). The extension of the transduced area centered around the site of injection, as observed by eGFP expression, was evaluated in consecutive sections and used for calculation of the total volume of the transduced brain parenchyma.
To identify the type of transduced cells in dissociated brain cultures and on mouse brain sections, double immune-labeling was performed using the rabbit antieGFP antibody (1:2000) in combination with each of the following cell type-specific mouse antibodies: anti-GFAP (Chemicon, Hampshire, UK, 1:1000) antibody or antiNeuN antibody (Chemicon, 1:500), and, as secondary antibodies, either the Alexa Fluor 488 goat antirabbit IgG (Molecular Probes, 1:100 (immunohistochemistry, IHC) or 1:250 (immunocytochemistry, ICC)) or the Alexa Fluor 568 goat antimouse IgG (Molecular Probes, 1:100 (IHC) or 1:250 (ICC)) so that in all images eGFP appears in green whereas the cell-specific marker proteins appear in red. Samples were fixed with 3.7% formalin solution and washed in PBS (pH 7.3). For ICC of dissociated cultures, cells were permeabilized with Triton X-100 for 30 min, and unspecific binding was blocked by serum (2% horse and 2% goat) for 90 min. Samples of brain sections were heat treated with citric acid (4 Â 5 min), washed in PBS and blocked with 1.5% goat serum for 30 min at room temperature before IHC. Both sections and cultures were then incubated with anti-eGFP/anti-NeuN or anti-GFAP at 41C overnight, washed with PBS and incubated with the secondary antibodies for 1 h (IHC) and 2 h (ICC) at room temperature. Samples were again washed with PBS, a coverslip was placed over the sample, and it was examined with a confocal laser scanning fluorescence microscope with appropriate filter settings (Axiovision System, Zeiss).
Quantification of infected cells
The volume fraction of eGFP positive cells within the reference volume of striatum and corpus callosum of the right hemisphere was estimated using a stereological point-grid method. The brain tissue blocks were sampled in a systematic uniform manner and from each brain, 5-15 (10 sections on average) 3 mm thick sections were selected for quantification. The distance between the two adjacent sections within all the series was 112 mm. A point-counting grid was placed over the micrographs and points hitting the positive cells, and the reference areas were counted. The volume of both positive cells and reference volume was calculated according to the Cavalieri principle. 57 Stereological analysis was carried out using the PointGrid module of the Ellipse3D software (ViDiTo, Kosice, Slovakia) connected to a scanning motorized XY stage (Maerzhaeuser, Wetzlar, Germany) of an Olympus BX51 microscope. To avoid bias of the results caused by irregular shape of the cell profiles, the total number of test points hitting the area of interest was estimated according to the nomogram of Gundersen and Jensen combined with a description of the shape of randomly selected eGFP-positive cells. 58 
Analysis of vector-specific immune response and biodistribution
To detect serum antibodies against the VSV-G protein, blood samples were taken from the heart of mice either infected with a VSV-G-pseudotyped lentiviral vector carrying the cPPT/CTS 5 weeks after vector injection into the brain or, as control, from a noninfected mouse. Serum was obtained from the coagulated blood and diluted 1:100. Five microliters of a concentrated VSV-G-pseudotyped virus vector solution per lane were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and blotted onto a nitrocellulose membrane (Hybond N+, Amersham Bioscience, Vienna, Austria). The membrane was cut into single lanes which were then incubated with individual mouse sera, followed by incubation with a rabbit antimouse antibody conjugated to HRP (1:10 000, Dako). Signals were detected using the enhanced chemiluminescence system (ECL, Amersham Bioscience). As control, an HRPconjugated monoclonal mouse anti-VSV-G antibody (Sigma, 1:5000) and serum from the noninjected mouse were used, respectively.
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